CASI Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
CASI Pharmaceuticals has a total shareholder equity of $24.2M and total debt of $18.9M, which brings its debt-to-equity ratio to 78.2%. Its total assets and total liabilities are $75.3M and $51.1M respectively.
Key information
78.2%
Debt to equity ratio
US$18.90m
Debt
Interest coverage ratio | n/a |
Cash | US$30.77m |
Equity | US$24.17m |
Total liabilities | US$51.10m |
Total assets | US$75.27m |
Recent financial health updates
We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate
Sep 02Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?
May 20Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?
May 26Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?
May 25Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth
Feb 18Recent updates
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%
Mar 12CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%
Dec 18We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate
Sep 02Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?
May 20Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M
Sep 23CASI Pharmaceuticals Q2 2022 Earnings Preview
Aug 11Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?
May 26Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts
Aug 14Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?
May 25Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?
Mar 16Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth
Feb 18How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?
Jan 23Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?
Dec 28CASI Pharma's CD19 CAR-T nabs accelerated review in China for a type of blood cancer
Dec 23CASI Pharmaceuticals appoints Weihao Xu as CFO
Dec 16Growth Investors: Industry Analysts Just Upgraded Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Revenue Forecasts By 4.3%
Dec 02The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Wei-Wu He, Just Bought 4.7% More Shares
Nov 27Casi Pharmaceuticals jumps 6% after CEO buys 227.5K shares
Nov 25Juventas initiates registration study for CNCT19
Nov 19CASI Pharmaceuticals EPS misses by $0.08, beats on revenue
Nov 09Financial Position Analysis
Short Term Liabilities: CASI's short term assets ($59.3M) exceed its short term liabilities ($16.7M).
Long Term Liabilities: CASI's short term assets ($59.3M) exceed its long term liabilities ($34.4M).
Debt to Equity History and Analysis
Debt Level: CASI has more cash than its total debt.
Reducing Debt: CASI's debt to equity ratio has increased from 1.4% to 78.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CASI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CASI has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 1.9% each year.